Our CEO David Hochman, joined the State of Medtech podcast to discuss all things Orchestra, from the partnership model behind our approach, to MedTech innovation, to what it really takes to bring high-impact therapies to patients.

Hear David break down how AVIM Therapy treats uncontrolled hypertension via a dual-chamber pacemaker, why partnerships are core to how Orchestra creates long-term value, and what separates the innovations strategics get excited about from the ones they pass on.
David Hochman on the State of Medtech Podcast
September 2026
David Hochman on the State of Medtech Podcast

Q2 2026 Progress Brings Key Pivotal Milestones Into View
August 2026
Q2 2026 Progress Brings Key Pivotal Milestones Into View

Q2 2026 Progress Brings Key Pivotal Milestones Into View Orchestra BioMed Investor Relations Blog | August 2026 Orchestr...

BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic
May 2026
BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic

BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic ...

Strategic Capital Supports Pivotal-Stage Execution
May 2026
Strategic Capital Supports Pivotal-Stage Execution

Strategic Capital Supports Pivotal-Stage Execution Orchestra BioMed Investor Relations Blog | May 2026 The receipt of $3...

Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation
April 2026
Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation

Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation Orchestra BioMed Investor ...

Follow us on LinkedIn
LinkedIn
LinkedIn Post

Avi Fischer, M.D., joined forward-thinking leaders exploring the future of treating hypertensive hea...

Learn more LinkedIn
LinkedIn Post

Great ideas need great minds to bring them to life. Our team is dedicated to making a lasting impact...

Learn more LinkedIn
LinkedIn Post

Where in the world is our CEO? 🌍 David Hochman joined leading voices in hashtag#Cardiology and hash...

Learn more LinkedIn
LinkedIn Post

Ligand Pharmaceuticals and Medtronic Cardiac and Vascular commit $70 Million in strategic capital to...

Learn more LinkedIn
LinkedIn Post

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT glo...

Learn more LinkedIn